• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用贝叶斯方法进行生物制品和疫苗的预测性能指数(Ppk)计算——教程

Predictive Ppk calculations for biologics and vaccines using a Bayesian approach - a tutorial.

作者信息

Weusten Jos, Hu Jianfang

机构信息

Center for Mathematical Sciences, MSD, Oss, The Netherlands.

Nonclinical Statistics, Pfizer, Collegeville, Pennsylvania, USA.

出版信息

Pharm Stat. 2025 Jan-Feb;24(1):e2380. doi: 10.1002/pst.2380. Epub 2024 Apr 11.

DOI:10.1002/pst.2380
PMID:38603591
Abstract

In pharmaceutical manufacturing, especially biologics and vaccines manufacturing, emphasis on speedy process development can lead to inadequate process development, which often results in less robust commercial manufacturing process after launch. Process performance index (Ppk) is a statistical measurement of the ability of a process to produce output within specification limits over a period of time. In biopharmaceutical manufacturing, progression in process development is based on Critical Quality Attributes meeting their specification limits, lacking insight into the process robustness. Ppk is typically estimated after 15-30 commercial batches at which point it may be too late/too complex to make process adjustments to enhance robustness. The use of Bayesian statistics, prior knowledge, and input from Subject matter experts (SMEs) offers an opportunity to make predictions on process capability during the development cycle. Developing a standard methodology to assess long term process capability at various stages of development provides several benefits: provides opportunity for early insight into process vulnerabilities thereby enabling resolution pre-licensure; identifies area of the process to prioritize and focus on during process development/process characterization (PC) using a data-driven approach; and ultimately results in higher process robustness/process knowledge at launch. We propose a Bayesian-based method to predict the performance of a manufacturing process at full manufacturing scale during the development and commercialization phase, before commercial data exists. Under Bayesian framework, limited development data for the process of interest at hand, data from similar products, general SME knowledge, and literature can be carefully formulated into informative priors. The implementation of the proposed approach is presented through two examples. To allow for continuous improvement during process development, we recommend to embed this approach of using predictive Ppk at pre-defined commercialization stage-gates, for example, at completion of process development, prior to and completion of PC, prior to technology transfer runs (Engineering/Process Performance Qualification, PPQ), and prior to commercial specification setting.

摘要

在制药生产中,尤其是生物制品和疫苗生产中,过于强调快速的工艺开发可能会导致工艺开发不足,这往往会导致产品上市后商业化生产工艺的稳健性较差。过程性能指数(Ppk)是衡量一个过程在一段时间内生产出符合规格限度的产品的能力的统计指标。在生物制药生产中,工艺开发的进展基于关键质量属性符合其规格限度,而缺乏对工艺稳健性的深入了解。Ppk通常在15至30个商业批次之后进行估算,此时进行工艺调整以提高稳健性可能为时已晚或过于复杂。使用贝叶斯统计、先验知识以及主题专家(SME)的意见,为在开发周期内预测工艺能力提供了机会。开发一种在不同开发阶段评估长期工艺能力的标准方法有诸多益处:能提供早期洞察工艺薄弱环节的机会,从而在获批前解决问题;使用数据驱动的方法确定工艺开发/工艺表征(PC)过程中需要优先考虑和关注的工艺领域;最终在产品上市时实现更高的工艺稳健性/工艺知识水平。我们提出一种基于贝叶斯的方法,用于在开发和商业化阶段、在商业数据存在之前预测全规模生产过程的性能。在贝叶斯框架下,可以将手头感兴趣的工艺的有限开发数据、来自类似产品的数据、SME的一般知识以及文献仔细整合为信息性先验。通过两个例子展示了所提方法的实施过程。为了在工艺开发过程中实现持续改进,我们建议在预定义的商业化阶段关卡嵌入这种使用预测性Ppk的方法,例如,在工艺开发完成时、在PC之前和完成时、在技术转移运行(工程/工艺性能确认,PPQ)之前以及在商业规格设定之前。

相似文献

1
Predictive Ppk calculations for biologics and vaccines using a Bayesian approach - a tutorial.使用贝叶斯方法进行生物制品和疫苗的预测性能指数(Ppk)计算——教程
Pharm Stat. 2025 Jan-Feb;24(1):e2380. doi: 10.1002/pst.2380. Epub 2024 Apr 11.
2
Multiproduct Resin Reuse for Clinical and Commercial Manufacturing-Methodology and Acceptance Criteria.用于临床和商业制造的多产品树脂再利用——方法与验收标准
PDA J Pharm Sci Technol. 2018 Nov-Dec;72(6):584-598. doi: 10.5731/pdajpst.2016.007245. Epub 2018 Jul 20.
3
Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.设备与分析公司面临持续挑战。2014年5月20 - 21日 连续制造研讨会
J Pharm Sci. 2015 Mar;104(3):821-31. doi: 10.1002/jps.24282. Epub 2014 Dec 1.
4
Quality risk management and data integrity in R&D laboratories supporting CMC lifecycle of biological products.研发实验室中的质量风险管理和数据完整性在支持生物制品 CMC 生命周期中的应用。
J Pharm Sci. 2024 Nov;113(11):3123-3136. doi: 10.1016/j.xphs.2024.09.013. Epub 2024 Sep 21.
5
Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.连续生物制药生产设施的产量优化
PDA J Pharm Sci Technol. 2017 May-Jun;71(3):189-205. doi: 10.5731/pdajpst.2016.006882. Epub 2016 Dec 14.
6
A cross-industry forum on benchmarking critical quality attribute identification and linkage to process characterization studies.跨行业基准测试关键质量属性识别和与工艺特征研究关联的论坛。
Biologicals. 2020 Sep;67:9-20. doi: 10.1016/j.biologicals.2020.06.008. Epub 2020 Jul 11.
7
Bayesian assurance and sample size determination in the process validation life-cycle.工艺验证生命周期中的贝叶斯保证与样本量确定
J Biopharm Stat. 2017;27(1):159-174. doi: 10.1080/10543406.2016.1148717. Epub 2016 Feb 18.
8
Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.连续制药生产中的控制系统工程。2014年5月20 - 21日,连续制造研讨会
J Pharm Sci. 2015 Mar;104(3):832-9. doi: 10.1002/jps.24311. Epub 2014 Dec 26.
9
Strategies for Maximizing Successful Drug Substance Technology Transfer Using Engineering, Shake-Down, and Wet Test Runs.
PDA J Pharm Sci Technol. 2015 Sep-Oct;69(5):650-7. doi: 10.5731/pdajpst.2015.01087.
10
White paper on continuous bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium.关于连续生物加工的白皮书。2014年5月20 - 21日连续制造研讨会。
J Pharm Sci. 2015 Mar;104(3):813-20. doi: 10.1002/jps.24268. Epub 2014 Nov 21.